Nuclear Medicine PET/CT Lymphomas Assessment, Protocols, and Interpretation
文献摘要
Positron emission tomography (PET) is a nuclear medicine imaging technique used in the diagnosis and monitoring of therapeutic response in various cancers, neurologic diseases, cardiovascular disorders, and infectious diseases. Unlike computed tomography (CT) and magnetic resonance imaging, which primarily provide anatomic detail, PET provides functional information at the molecular level, enabling the detection of metabolically active disease before morphologic abnormalities become apparent. Hybrid imaging with fluorine-18 fluorodeoxyglucose (FDG) PET/CT combines functional and anatomic information and has become integral to cancer staging, treatment response assessment, and disease surveillance. Although multiple positron-emitting radiotracers are under investigation, FDG remains the most widely available and commonly used radiopharmaceutical in oncology. Emerging technologies, including artificial intelligence, fibroblast activation protein inhibitor (FAPI) PET, and immunoPET, may further enhance lymphoma imaging and therapeutic decision-making in the future. FDG remains the most widely available and increasingly utilized radiopharmaceutical in cancer management. This resource focuses on the role of FDG PET/CT in lymphoma management.